Report description
Autoimmune disorders result from an overactive immune response of a body working against its own cells. The disease is broadly classified into two types: systemic autoimmune diseases, which affect several organs of the body; and localized autoimmune diseases, which affect only one organ. Around 80 autoimmune diseases are recognized under these two categories. The disease affected over 300 million people across the globe in 2009. No defined reasons have been discovered to date for the occurrence of the disorder. Women are more prone to autoimmune diseases, constituting 70%-75% of all autoimmune patients.
The overall market for the treatment of autoimmune disorders is analyzed into the submarkets for applications, products, services, and technologies. The global market for autoimmune disease treatments is estimated to be at $37.84 billion in 2009, and is growing at a CAGR of 12.7% from 2009 to 2014 to reach an estimated $68.81 billion in 2014. The effects of the global meltdown are given careful consideration when forecasting the market.
The application market is further classified into the treatment markets for systemic autoimmune diseases and localized autoimmune diseases. The applications market is dominated mostly by rheumatoid arthritis under the systemic disease segment, while multiple sclerosis is the major application market under the localized disease segment. These two disorders account for 75% of the total applications market. The other major diseases analysed under the application market are psoriasis, lupus, type I diabetes, inflammatory bowel disease, and thyroid disorders, which together account for 15%-20% of the global applications market.
The product market is classified on the basis of the drugs, diagnostic equipments, therapeutic and monitoring equipment. Drugs form the largest segment of the products market, with major drugs such as NSAID, DMARD, biologic DMARD, Avonex, Rebif, Copaxone, Betaseron, and 5-ASA. The services market consists of consultation and diagnosis, therapy and monitoring, and drug development. The wide and increasing prevalence of autoimmune diseases is boosting the drugs market along with the therapy and monitoring market; along with the fact that almost all autoimmune diseases are chronic and have no permanent cure.
The drugs market is estimated to have a revenue of $24.38 billion in 2009, and it is growing with a CAGR of 12.5% from 2009 to 2014. The total services market with therapy and monitoring and drug development as the largest contributor is estimated to be at $9.31 billion in 2009 and it is growing at a CAGR of 14% from 2009 to 2014.
Scope of the Report
- The report provides market overviews and forecasts as well as market drivers and restraints for the global autoimmune treatment market. In addition, it profiles the top forty market players and their respective autoimmune products. The report identifies and analyzes the market according to application markets for both systemic and localized autoimmune diseases, product markets, services market and technologies market.
Autoimmune Treatment – Applications
- Systemic autoimmune diseases – rheumatoid arthritis, psoriasis, lupus, and other systemic autoimmune diseases.
- Localized autoimmune diseases – multiple sclerosis, inflammatory bowel disease, diabetes, thyroid, and other localized autoimmune diseases.
Autoimmune Treatment – Products
Drugs, diagnostic equipment, therapeutic and monitoring equipment, and other products.
Autoimmune Treatment – Services
Consultation & Diagnosis, Therapy & Monitoring, Drug Development, and other services.
Autoimmune Treatment – Technologies
DMARD (disease-modifying anti-rheumatic drugs) and biologic DMARD therapy, Bridge therapy, Topical therapy, Phototherapy, Helminthic therapy, Fecal bacteriotherapy, Haematopoietic stem-cell transplantation, Recombinant technology
What makes our reports unique?
- We provide the longest market segmentation chain in this industry- not many reports provide market breakdown upto level 4.
- Each report is about 250 pages with 100+ market data tables, 40 competitive company profiles, analysis of 200 patents and minimum 40 micro markets, which are collectively exhaustive and mutually exclusive.
- No single report by any other publisher provides market data for all the segments viz products, services, applications, ingredients, technology, and stakeholders in a single report for all the four geographies – North America, Europe, Asia Pacific and ROW.
- We provide 10% customization- normally it is seen that clients do not find specific market intelligence that they are looking for. Our customization will ensure that you necessarily get the market intelligence you are looking for and we get a loyal customer.
- 15 pages of high level analysis including benchmarking strategies, best practices (five level of products) and the market’s cash cows (BCG matrix). We conduct detailed market positioning, product positioning and competitive positioning. Entry strategies, gaps and opportunities are identified for all the stakeholders.
Key questions answered
- Which are the high-growth segments/cash cows and how is the market segmented in terms of applications, products, services, ingredients, technologies, stakeholders?
- What are market estimates and forecasts; which markets are doing well and which are not?
- Where are the gaps and opportunities; what is driving the market?
- Which are the key playing fields? Which are the winning edge imperatives?
- How is the competitive outlook; who are the main players in each of the segments; what are the key selling products; what are their strategic directives, operational strengths and product pipelines? Who is doing what?
Powerful Research and analysis
- The analysts working with MarketsandMarkets come from renowned publishers and market research firms, globally, adding their expertise and domain understanding. We get the facts from over 22,000 news and information sources, a huge database of key industry participants and draw on our relationships with more than 900 market research companies
Table of Content 1. Chapter one - Introduction
1.1. KEY TAKE AWAYS
1.2. Report description
1.3. Markets Covered
1.4. STAKEHOLDERS
2. Chapter Two – Summary
3. Chapter Three – Market Overview
3.1. Evolution for Autoimmune treatments
3.2. FOCUS AREAS for the DEVELOPMENT autoimmune treatment
3.3. Defining the overall autoimmune treatment market
3.4. Defining the Autoimmune treatment market by geography
4. Chapter four – global autoimmune treatment market by application
4.1. Systemic Autoimmune Diseases
4.2. Rheumatoid Arthritis (RA)
4.2.1. Drivers
4.2.1.1. Large number of people suffer from RA
4.2.1.2. RA requires continuous treatment as it is a chronic disease
4.2.1.3. Large middle adulthood population is more prone to RA
4.2.2. Restraints
4.2.2.1. No fixed treatment is available for RA
4.2.2.2. Fewer insurance coverage and reimbursement for RA treatment
4.2.3. Global RA Market for Consultation & Diagnosis
4.2.4. Global RA market for therapy & monitoring
4.2.4.1. Global DMARD and biologic DMARD Therapy in RA
4.2.4.2. Global Bridge Therapy market in RA
4.2.4.3. Global Other Therapies market in RA
4.2.5. Global RA Market for Drugs
4.2.5.1. Global NSAID market in RA
4.2.5.2. Global Corticosteroids Market in RA
4.2.5.3. Global Other Drugs Market in RA
4.2.6. Global other products and services market in RA
4.2.7. Drug Approvals
4.3. Psoriasis
4.3.1. Drivers
4.3.1.1. Psoriasis starts at early age, gives a long earning period
4.3.1.2. Large patient base is driving the market
4.3.1.3. Psoriasis is also genetically transferred
4.3.2. Market restraints
4.3.2.1. Over the counter (OTC) drugs can result into adverse drug reactions (ADRs)
4.3.2.2. No specific diagnosis and treatment hinders the market growth
4.3.3. Global Consultation & Diagnosis Market in Psoriasis
4.3.4. Global therapy & monitoring market in psoriasis
4.3.5. Global Drugs Market in Psoriasis
4.3.5.1. Global Anthralin Market in Psoriasis
4.3.5.2. Global Calcipotriene Market in Psoriasis
4.3.5.3. Global NSAIDs market in Psoriasis
4.4. Lupus
4.5. Other Systemic Diseases
4.6. Localized autoimmune Diseases
4.7. Multiple Sclerosis (MS)
4.7.1. Drivers
4.7.1.1. MS is a chronic disorder which requires lifetime treatment
4.7.1.2. Large number of MS patients across the globe
4.7.1.3. Increased public awareness is leading to early initiation of treatment
4.7.1.4. Combination of therapies is increasing the growth opportunities
4.7.2. Restraints
4.7.2.1. Complicated nature of disease with limited drugs is hindering the market growth
4.7.2.2. Side effects of injectables and high cost of oral drugs is affecting the growth
4.7.3. Global Drugs market in multiple sclerosis
4.7.4. Drug Approval
4.8. Inflammatory Bowel Disease (IBD)
4.8.1. Drivers
4.8.1.1. IBD a genetically transferred disease, increases the incidence of cases
4.8.1.2. Early treatment of IBD is driving the market
4.8.1.3. Lifelong treatment gives a long earning period
4.8.2. Restraints
4.8.2.1. Insurance coverage reimbursement problems for IBD patients
4.8.3. Global Consultation & Diagnosis Market in IBD
4.8.4. Global therapy & monitoring market in IBD
4.8.5. Global drugs market in IBD
4.9. Type I diabetes
4.9.1. Easy insurance coverage for diabetes patients
4.9.2. Type I diabetes is still considered to be a chronic disorder
4.9.3. Casual behavior towards treatment is restraining the Market growth
4.10. Thyroid
4.11. Other Localized Autoimmune diseases
5. Chapter five – Global Autoimmune treatment Market By Product
5.1. Drugs
5.1.1. Non-Steroidal anti-inflammatory drugs (NSAID)
5.1.1.1. Drivers
5.1.1.2. Restraints
5.1.2. GLUCOCORTICOIDS
5.1.3. METHOTREXATE
5.1.3.1. Drivers & Restraints
5.1.4. Hydroxychloroquine (HCQ)
5.1.4.1. Drivers
5.1.4.2. Restraints
5.1.5. Anthralin
5.1.6. Calicipotriene
5.1.7. Corticosteriods (Steriods)
5.1.8. Aminosalicylates/5-ASA/Mesalazine
5.1.9. Avonex
5.1.10. Rebif
5.1.11. Copaxone
5.1.11.1. Fewer side effects is increasing the demand
5.1.11.2. Reduces relapses in relapsing-remitting multiple sclerosis (RRMS)
5.1.12. Betaseron
5.1.13. Comparison of four MS drugs
5.1.14. Other Drugs
5.2. Diagnostic equipment
5.3. Therapeutic and monitoring equipment
5.4. Other Products
6. Chapter six – global services market in autoimmune treatment
6.1. Consultation & Diagnosis
6.2. Therapy and monitoring
6.3. Drug Development
6.4. Drivers
6.4.1. Drugs form the mainstream, most revenue-generating treatment
6.4.2. Introduction of biosimilars opens up more opportunities
7. Chapter seven – global Technology market in autoimmune treatment
7.1. DMARD AND BIOLOGIC DMARD THERAPY
7.1.1. Drivers
7.1.1.1. Effective therapies with biologic DMARD and the availability of multiple drugs
7.1.1.2. Cost-effective treatment is boosting the demand for the therapy
7.1.2. Restraints
7.2. Bridge Therapy
7.3. Topical Therapy
7.4. Fecal Bacteriotherapy
7.5. Helminthic Therapy
7.5.1. Drivers & Restraints
7.5.1.1. Higher efficacy
7.5.1.2. Expensive treatment hindering the market growth
7.6. Hematopoietic stem cell transplantation
7.6.1. Drivers & Restraints
7.7. Recombinant Technology
8. Chapter Eight – Global Autoimmune Treatment Market by Geography
8.1. Autoimmune treatment market in North America
8.1.1. North American Autoimmune treatment Market by
8.1.2. Application
8.2. Autoimmune treatment market in Europe
8.2.1. European autoimmune treatment market by application
8.3. Autoimmune treatment market in Asia Pacific
8.4. Autoimmune treatment market in ROW
9. Chapter Nine – Patent Analysis
9.1. Analysis of patents by geography
10. Chapter Ten – Company Profiles
10.1. 4SC AG
10.2. Abbott Laboratories
10.3. Active Biotech
10.4. Amgen
10.5. Angiotech Pharmaceuticals
10.6. Astellas Pharma
10.7. AstraZeneca Plc
10.8. Autoimmune Inc
10.9. Bayer-Schering Pharmaceuticals
10.10. BioCryst Pharmaceuticals Inc.
10.11. Biogen Idec, Inc.
10.12. Boehringer Ingelheim Gmbh
10.13. Bristol-Myers Squibb Co.
10.14. Centocor, Inc
10.15. Cytokine PharmaSciences, Inc
10.16. Elan Corporation, plc
10.17. Eli Lilly & Co.
10.18. Forest Laboratories, Inc.
10.19. Galderma Laboratories
10.20. Genentech, Inc.
10.21. Glaxo SmithKline Plc
10.22. Isis Pharmaceuticals, Inc.
10.23. Isotechnika, Inc.
10.24. Johnson & Johnson
10.25. Ligand Pharmaceuticals
10.26. Lupin
10.27. Merk Serono SA
10.28. Mitsubishi Tanabe Pharma Corporation
10.29. Novartis
10.30. Pfizer
10.31. Roche
10.32. Sanofi-Aventis
10.33. Schering-Plough
10.34. Teva
10.35. UCB Pharma Inc
10.36. Vertex Pharmaceuticals Incorporated
10.37. Warner Chilcott
10.38. Watson Pharmaceuticals, Inc
10.39. Wyeth
10.40. ZymoGenetics, Inc.
Appendix
1. Table 1
2. U.S. patents
3. Source: MarketsandMarkets
4. Europe Patent List
5. Source: MarketsandMarkets
6. Table 2
7. Japan Patent Table
8. Source: MarketsandMarkets
List of Tables
Summary Table GLOBAL MARKET FORECAST FOR Autoimmune treatment BY Application 2007 – 2014 ($ Millions)
Table 1 Global Autoimmune treatment market by products and services
Table 2 Global systemic diseases market by application 2007 – 2014 ($ Millions)
Table 3 Global Systemic diseases market, by geography 2007 – 2014 ($ Millions)
Table 4 Global rheumatoid arthritis market by Application, 2007 – 2014 ($ millions)
Table 5 Global rheumatoid arthrits Application market, by geography 2007 – 2014 ($ Millions)
Table 6 Global RA consultation & diagnosis market, by geography 2007 – 2014 ($ millions)
Table 7 Global RA therapy and monitoring market, by technologies, 2007 – 2014 ($ millions)
Table 8 Global RA therapy and monitoring market, By geography 2007 – 2014 ($ millions)
Table 9 Global DMARD and biologic DMARD Therapy in RA, By geography 2007 – 2014 ($ millions)
Table 10 Global Bridge Therapy market in RA, By geography 2007 – 2014 ($ millions)
Table 11 Global other therapies market in ra, By geography 2007 – 2014 ($ millions)
Table 12 Global RA drugs market by product, 2007 – 2014 ($ millions)
Table 13 Global ra drugs market, by geography 2007 – 2014 ($ millions)
Table 14 Global NSAID market in ra, by geography 2007 – 2014 ($ millions)
Table 15 Global Corticosteriods market in ra, 2007 – 2014 ($ Millions)
Table 16 Global Other Drugs Market in RA, by geography 2007 – 2014 ($ Millions)
Table 17 Global other products and services market in RA, by geography 2007 – 2014 ($ millions)
Table 18 Major Companies and products in RA Application
Table 19 Merger and Acquisition activities in RA market
Table 20 Global psoriasis market by application, by product 2007 – 2014 ($ millions)
Table 21 Global psoriasis Application Market, by geography 2007 – 2014 ($ Millions)
Table 22 Global psoriasis consultation & Diagnosis market, 2007 – 2014 ($ millions)
Table 23 Global therapy & monitoring market in psoriasis by technologies, 2007 – 2014 ($ millions)
Total 24 Global psoriasis therapy and monitoring market, 2007 – 2014 ($ millions)
Table 25 Global Drugs Market in psoriasis, by product 2007 – 2014 ($ millions)
Table 26 Global psoriasis Drugs Market, by geography 2007 – 2014 ($ millions)
Table 27 Global Anthralin Psoriasis Market, by geography 2007 – 2014 ($ millions)
Table 28 Global Calcipotriene Psoriasis Market, by geography 2007 – 2014 ($ millions)
Table 29 Global NSAID Psoriasis Market, by geography 2007 – 2014 ($ millions)
Table 30 Major Companies and Their products in psoriasis
Table 31 Mergers & Acquisition activities in Psoriasis Market
Table 32 Global Lupus market by application, 2007 – 2014 ($ millions)
Table 33 Global Lupus market, by geography 2007 – 2014 ($ millions)
Table 34 Global other systemic autoimmune diseases market by application 2007 – 2014 ($ millions)
Table 35 Global other systemic autoimmune diseases market, by geography 2007 – 2014 ($ millions)
Table 36 Global Localized market by application, 2007 – 2014 ($ Millions)
Table 37 Global Localized Disease Market, by geography 2007 – 2014 ($ Millions)
Table 38 Global Multiple Sclerosis Application Market, 2007 – 2014 ($ millions)
Table 39 Global Multiple Sclerosis Application Market, by geography 2007 – 2014 ($ millions)
Table 40 Global Drugs market in MS, by product 2007 – 2014 ($ millions)
Table 41 Major companies and products in MS Application
Table 42 Mergers & Acquisition activities in MS application
Table 43 Global Inflammatory Bowel Disease market by application 2007 – 2014 ($ millions)
Table 44 Global Inflammatory Bowel Disease market, by geography 2007 – 2014 ($ millions)
Table 45 Global Consultation & diagnosis market in IBD, by geography 2007 – 2014 ($ millions)
Table 46 Global therapy & monitoring market in IBD, by product 2007 – 2014 ($ millions)
Table 47 Global Drugs market in IBD, by product 2007 – 2014 ($ millions)
Table 48 Global IBD Drugs market, by region 2007 – 2014 ($ millions)
Table 49 Major Companies and Products in IBD market
Table 50 Mergers and Acquisition activities in IBD market
Table 51 Global type I diabetes market by application, 2007 – 2014 ($ millions)
Table 52 Global type I diabetes market, by geography 2007 – 2014 ($ millions)
Table 53 Major Companies and products in type I diabetes market
Table 54 Mergers and Acquisition activities in type I diabetes market
Table 55 Global Thyroid market BY APPLICATION 2007 – 2014 ($ Millions)
Table 56 Global Thyroid Market, by geography 2007 – 2014 ($ Millions)
Table 57 Global other localized autoimmune diseases Market by application, 2007 – 2014 ($ Millions)
Table 58 Global other localized autoimmune diseases Market, by geography 2007 – 2014 ($ Millions)
Table 59 Global Autoimmune treatment market by product 2007 – 2014, ($ Millions)
Table 60 Global Autoimmune treatment products market by geography 2007 – 2014, ($ Millions)
Table 61 Global autoimmune drugs market, by product, 2007 – 2014,($ Millions)
Table 62 Global autoimmune drugs market by geography 2007 – 2014, ($ Millions)
Table 63 Global NSAID market in autoimmune treatment by geography 2007 – 2014 ($ millions)
Table 64 Global Glucocorticoids market in autoimmune treatment by geography 2007 – 2014 ($ millions)
Table 65 Global Methorexate market in autoimmune treatment by geography 2007 – 2014 ($ millions)
Table 66 Global Hydroxychloroquine market in autoimmune treatment, by geography 2007 – 2014 ($ millions)
Table 67 Global Hydroxychloroquine market in autoimmune treatment, by geography 2007 – 2014 ($ millions)
Table 68 Global Calcipotriene market in autoimmune treatment by geography 2007 – 2014 ($ millions)
Table 69 Global Corticosteriods market in autoimmune treatment, by geography 2007 2014 ($ millions)
Table 70 Global Aminosalicylates/5-ASA/Mesalazine market in autoimmune treatment, by geography 2007 – 2014 ($ millions)
Table 71 Global Avonex market in autoimmune treatment by geography 2007 – 2014 ($ millions)
Table 72 Global Rebif market in autoimmune treatment by geography 2007 – 2014 ($ millions)
Table 73 Global Copaxone market in autoimmune treatment by geography 2007 – 2014 ($ millions)
Table 74 Global betaseron market in autoimmune treatment by geography 2007 – 2014 ($ millions)
Table 75 Global other autoimmune drugs market by geography 2007 – 2014 ($ millions)
Table 76 Global autoimmune diagnostic equipment market by product 2007 – 2014 ($ millions)
Table 77 Global autoimmune diagnostic equipment market by geography 2007 – 2014 ($ millions)
Table 78 Global autoimmune therapeutic and monitoring equipment market by geography 2007 – 2014 ($ millions)
Table 79 Global other autoimmune products market by geography 2007 – 2014 ($ millions)
Table 80 Global Services market in autoimmune treatment 2007 – 2014 ($ millions)
Table 81 Global Services market in autoimmune treatment by geography 2007 – 2014 ($ millions)
Table 83 Global autoimmune Consultation & diagnosis market, by geography 2007 – 2014 ($ millions)
Table 84 Global autoimmune therapy & monitoring market by geography 2007 – 2014 ($ millions)
Table 85 Global autoimmune Drug Development market by geography 2007 – 2014 ($ millions)
Table 86 Global autoimmune treatment technology market by product 2007 – 2014 ($ millions)
Table 87 Global autoimmune treatment technology market by geography 2007 – 2014 ($ millions)
Table 88 Global DMARD and biologic dmard technology market by geography 2007 – 2014 ($ millions)
Table 89 Global autoimmune topical therapy market by geography 2007 – 2014 ($ millions)
Table 90 Global autoimmune Helminthic therapy market by geography 2007 – 2014 ($ millions)
Table 91 Global autoimmune Hematopoietic stem cell transplantation market, by geography 2007 – 2014 ($ millions)
Table 92 Global autoimmune Recombinant Technology Market by geography 2007 – 2014 ($ millions)
Table 93 Global forecast for autoimmune treatment market 2007 – 2014 ($ Millions)
Table 94 North American market for autoimmune treatment by application 2007 – 2014 ($ millions)
Table 95 European market for autoimmune treatment by application 2007 – 2014 ($ millions)
Table 97 ASIA PACIFIC market for autoimmune treatment by application2007 – 2014 ($ millions)
Table 98 ROW MARKET for autoimmune treatment, by application 2007 – 2014 ($ millions)
List of Figures
Figure 1 Figure for the classification of autoimmune diseases by application
Figure 2 Comparison of four major drugs in MS application
Figure 3 Expected causes of autoimmune diseases
Figure 4 Chronology of evolution of therapies and drugs
Figure 5 Focus levels for the growth in autoimmune treatment
Figure 6 Global autoimmune market, by geography
Figure 7 Positioning various applications in the market for autoimmune treatment
Figure 8 Market Share of autoimmune Drugs in 2009
Figure 9 European Markets for Autoimmune Treatment, In 2009 (%)
Figure 10 Number of patents issued (January 2004 – June 2009)
Figure 11 Number of patents issued by geography (January 2004 – June 2009)
Figure 12 Geographical analysis (January 2004 – June 2009)
Autoimmune Treatment Market
Autoimmune disorders result from an overactive immune response of a body working against its own cells. The disease is broadly classified into two types: systemic autoimmune diseases, which affect several organs of the body; and localized autoimmune diseases, which affect only one organ. Around 80 autoimmune diseases are recognized under these two categories. The disease affected over 300 million people across the globe in 2009. No defined reasons have been discovered to date for the occurrence of the disorder. Women are more prone to autoimmune diseases, constituting 70%-75% of all autoimmune patients.
The overall market for the treatment of autoimmune disorders is analyzed into the submarkets for applications, products, services, and technologies. The global market for autoimmune disease treatments is estimated to be at $37.84 billion in 2009, and is growing at a CAGR of 12.7% from 2009 to 2014 to reach an estimated $68.81 billion in 2014. The effects of the global meltdown are given careful consideration when forecasting the market.
The application market is further classified into the treatment markets for systemic autoimmune diseases and localized autoimmune diseases. The applications market is dominated mostly by rheumatoid arthritis under the systemic disease segment, while multiple sclerosis is the major application market under the localized disease segment. These two disorders account for 75% of the total applications market. The other major diseases analysed under the application market are psoriasis, lupus, type I diabetes, inflammatory bowel disease, and thyroid disorders, which together account for 15%-20% of the global applications market.
The product market is classified on the basis of the drugs, diagnostic equipments, therapeutic and monitoring equipment. Drugs form the largest segment of the products market, with major drugs such as NSAID, DMARD, biologic DMARD, Avonex, Rebif, Copaxone, Betaseron, and 5-ASA. The services market consists of consultation and diagnosis, therapy and monitoring, and drug development. The wide and increasing prevalence of autoimmune diseases is boosting the drugs market along with the therapy and monitoring market; along with the fact that almost all autoimmune diseases are chronic and have no permanent cure.
The drugs market is estimated to have a revenue of $24.38 billion in 2009, and it is growing with a CAGR of 12.5% from 2009 to 2014. The total services market with therapy and monitoring and drug development as the largest contributor is estimated to be at $9.31 billion in 2009 and it is growing at a CAGR of 14% from 2009 to 2014.
Each segment is analyzed and forecasts are for four geographical regions – North America, Europe, Asia Pacific, and Rest of World (ROW). The North American market includes U.S. and Canada. The European market includes Germany, France, U.K. and other countries in European continent. The major Asia Pacific markets include Japan, Australia, China, India, Singapore and Malaysia. Mexico has been considered in the ROW category along with Middle East, Russia and South Africa.
North America is the largest market for autoimmune treatment with a 42% share of the global market, followed by Europe with a 30% share. However, Asia Pacific with a 20% market share is the fastest-growing market with a 13.3% CAGR from 2009 to 2014
Source: http://www.pharma-market-reports.com/
